简介:AIM:TocomprehensivelyevaluatethepotentialassociationofCOL1A1polymorphismswithhighmyopiabyasystematicreviewandMeta-analysis.METHODS:AllassociationstudiesonCOL1A1andhighmyopiareporteduptoJune10,2014inPubMed,Embase,WebofScience,andtheChineseBiomedicalDatabasewereretrieved.Oddsratios(ORs)and95%confidenceintervals(95%CIs)wereanalyzedforsinglenucleotidepolymorphisms(SNPs)usingfixed-andrandom-effectsmodelsaccordingtobetween-studyheterogeneity.PublicationbiasanalyseswereconductedbyEgger’stest.RESULTS:Atotaloffourstudiesfromreportedpaperswereincludedinthisanalysis.TheMeta-analysesforCOL1A1rs2075555,composedof2304highmyopiapatientsand2272controls,failedtodetectanysignificantassociationwithhighmyopia.Atotalof971casesand649controlsweretestedforCOL1A1rs2269336.TheassociationofCOL1A1rs2269336withhighmyopiawasobservedinrecessivemodel(CCvsCG+GG,P=0.03)andinheterozygousmodel(CGvsGG,P=0.04),butnotinothermodels.CONCLUSION:ThisMeta-analysisshowsthatCOL1A1rs2269336(CCvsCG+GG)affectsindividualsusceptibilitytohighmyopia,whereasthereisnoassociationdetectedbetweenSNPsrs2075555andhighmyopia.Giventhelimitedsamplesize,furtherinvestigationsincludingmoreethnicgroupsarerequiredtovalidatetheassociation.
简介:患者,男,51岁,2004年8月因“左眼颈椎手术后视物不见2个月”至本院就诊。左眼:视力无光感,眼球各方向运动中度受限,屈光介质透明,瞳孔散大,直接对光(-),间接对光反应迟钝,视网膜灰黄色,血管变细,视乳头苍白,脉络膜背景污秽色,眼底无出血渗出。右眼:无阳性体征。现病史:患者2004年6月因“无骨折脱位性颈脊髓损伤并不全瘫”在当地医院行颈椎手术。麻醉方式:静脉复合麻醉,俯卧,颈部过伸位。手术持续时间:4小时40分。术前患者双眼视力均正常,苏醒后即左眼视物完全不见,右眼正常,当地医院眼科检查治疗情况不详。我院诊断:左眼部缺血综合征。
简介:DearEditor,IamSatoruKase,fromtheDepartmentofOphthalmology,FacultyofMedicineandGraduateSchoolofMedicine,HokkaidoUniversity,SapporoCity,Japan.Iwritetopresentacaseofneurofibromatosistype1(NF1)showingmassivehemorrhageduringinvolutionalblepharoptosissurgery.
简介:目的通过观察中药川芎嗪联合西药氨基胍治疗对糖尿病早期大鼠视网膜组织醛糖还原酶(aldosereductase,AR)和一氧化氮合酶(nitricoxidesynthase,NOS)含量的影响,探讨中西药治疗糖尿病视网膜病(dirabeticretinopathy,DR)的治疗机制.方法选择健康成年雄性SD大鼠,随机分成正常对照组、糖尿病组、糖尿病川芎嗪治疗组、糖尿病氨基胍治疗组和糖尿病川芎嗪联合氨基胍治疗组.一次性腹腔注射链脲佐菌素(streptozotocin,STZ)诱发糖尿病模型,于第90d测定各组大鼠视网膜组织AR和NOS含量.结果糖尿病川芎嗪治疗组、糖尿病氨基胍治疗组和糖尿病川芎嗪联合氨基胍治疗组的大鼠视网膜组织AR和NOS含量低于糖尿病组、糖尿病川芎嗪联合氨基胍治疗组的大鼠视网膜组织AR和NOS含量低于糖尿病川芎嗪治疗组和糖尿病氨基胍治疗组.结论结合以往观察的川芎嗪联合氨基胍治疗对大鼠眼底和视网膜组织学的影响结果,川芎嗪和氨基胍可通过降低糖尿病早期大鼠视网膜AR和NOS含量而防治DR,联合用药效果更佳.